New eye drug trial aims for safer wet AMD treatment
Disease control
Ongoing
This early-stage trial tests an experimental drug called OCU-10-C-110, given as an eye injection, in 24 people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability at different doses. Researchers will monitor for side effects over ti…
Phase: PHASE1 • Sponsor: Ocugenix Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC